Renal Neuroendocrine Neoplasms: A Single-center Experience

Patrick W. McGarrah, Gustavo F.M. Westin, Timothy J. Hobday, Joseph A. Scales, Johann P. Ingimarsson, Bradley C. Leibovich, Thorvardur R. Halfdanarson

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Renal neuroendocrine neoplasms are rare, with little to no data available on prognosis and treatment outcomes. We present the largest single-institution series of 17 patients, with a median follow-up of 62.8 months. After aggressive resection, the median time to recurrence was 18 months, and the median overall survival was 143 months. Somatostatin analogs provided disease stability in 4 of 9 patients.

Original languageEnglish (US)
Pages (from-to)e343-e349
JournalClinical Genitourinary Cancer
Issue number4
StatePublished - Aug 2020


  • Horseshoe kidney
  • Kidney carcinoid
  • Rare cancers
  • Renal carcinoid
  • Renal neuroendocrine carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Renal Neuroendocrine Neoplasms: A Single-center Experience'. Together they form a unique fingerprint.

Cite this